The U.S. Food and Drug Administration (FDA) has approved Mesoblast Ltd.'s mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD), marking a pivotal moment in regenerative medicine. This approval signifies the first MSC-based therapy available for this challenging condition.
Pluri Inc., a company focused on cell-based technologies, congratulated Mesoblast on this achievement. Yaky Yanay, Chief Executive Officer and President of Pluri, stated, "This milestone is not just a triumph for Mesoblast, but for the entire field of cellular medicine. This approval validates the immense therapeutic promise of MSCs and inspires all of us working in this space to redouble our efforts to bring innovative solutions to patients in need."
Impact on Regenerative Medicine
The FDA approval underscores the transformative potential of regenerative medicine in healthcare. Regenerative therapies aim to address the root causes of diseases, potentially improving patient outcomes and creating more sustainable healthcare systems. MSCs, with their ability to modulate the immune system and promote tissue repair, hold promise for treating various conditions.
Pluri's Perspective
Pluri has been a long-time advocate for MSCs, utilizing its 3D cell-expansion technology to develop scalable cell-based therapies. The company believes that the FDA's decision highlights the importance of accelerating the development of MSC-based therapies worldwide.
Pluri's PLacental eXpanded cells are placenta-derived, mesenchymal-like adherent stromal cells which are being studied for the treatment of hematopoietic indications such as Acute Radiation Syndrome as well as orthopedic indications such as Knee Osteoarthritis.
